SuperworthBioRestorative Therapies BRTX
- Market cap
- $2.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 5.8×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $357.9K
- −8% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- Q1 FY26 missing
BioRestorative Therapies trades at 5.8× sales. Its trailing earnings are negative, so it has no PE. Revenue was $357.9K over the last twelve months, down 8% on a year earlier.
Charts
Financials
| Income statement | Q2 FY23 | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $64.5K−9% | $30.7K+6% | $19.3K+422% | $35K+12% | $89.1K+38% | $233.6K+661% | $43.3K+124% | $25K−29% | $303.3K+240% | $11.8K−95% | $19.6K−55% | $23.2K−7% | |
| Cost of revenue | n/a | n/a | n/a | n/a | $6.5K | $18.2K | $3.3K | $2.9K | $8.7K+35% | $10.6K−42% | $1.6K−51% | $7.4K+154% |
| Gross profit | $64.5K | $30.7K | $19.3K | $35K | $82.6K+28% | $215.4K+602% | $40K+107% | $22.1K−37% | $294.6K+257% | $1.2K−99% | $18K−55% | $15.8K−29% |
| R&D | $902.9K−16% | $809.8K−18% | $1.1M+62% | $1.1M−14% | $1.5M+61% | $1.5M+80% | $1.7M+56% | $2.6M+150% | $2.2M+53% | $2.6M+79% | $2.6M+54% | $1.9M−27% |
| SG&A | $2.3M−37% | $2.3M−36% | $2.1M−46% | $3.1M−33% | $1.1M−52% | $1M−55% | $1M−52% | $2.2M−29% | $1.4M+25% | $1.1M+6% | $1.2M+18% | $1.5M−32% |
| −$3.1M−33% | −$3.1M−33% | −$3.2M−31% | −$4.1M−29% | −$2.5M−21% | −$2.3M−26% | −$2.7M−17% | −$4.8M+17% | −$3.3M+34% | −$3.7M+62% | −$3.8M+42% | −$3.4M−30% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$5.7M+22% | $4.8M | −$2.3M−47% | −$2.2M−69% | −$4M−29% | −$1.1M | −$1.6M−29% | −$5.3M+140% | −$2.7M−34% | −$3M+178% | −$3.2M+96% | −$2.2M−60% |
| −$29.40+15% | $7.80 | −$9.80−59% | −$6.60−83% | −$10.00−66% | −$2.60 | −$4.00−59% | −$12.80+94% | −$6.00−40% | −$6.60+154% | −$6.60+65% | −$2.40−81% | |
| 194.3K+7% | 616.2K+238% | 234.1K+28% | 333.6K+80% | 406.1K+109% | 406.1K−34% | 406.1K+74% | 417.9K+25% | 437K+8% | 455.8K+12% | 486.9K+20% | 886.4K+112% |
EPS, diluted: 19 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 16 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest BioRestorative Therapies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BRTXBioRestorative Therapies | $2.1M | n/m | n/a | 5.8× | −8% | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| MDRRMedalist Diversified | $15.4M | 2.5× | 3.0× | 1.6× | −1% | 80.2% | |
| BCGBinah Capital | $18.2M | 6.7× | 20.8× | 0.1× | +8% | 2.2% | |
| VIPVulcan Infrastructure & Power | $19.6M | 17.9× | 24.4× | 0.4× | −14% | 1.0% | |
| MXCMexco Energy | $20.5M | 13.4× | 13.3× | 3.0× | −9% | 23.3% | |
| Peer median | $15.4M | 6.7× | 13.3× | 0.4× | −6% | 4.7% |
More on BioRestorative Therapies
Each number over time
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .